Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Gains from Investment Securities: 2013-2024

Historic Gains from Investment Securities for Capricor Therapeutics (CAPR) over the last 5 years, with Dec 2024 value amounting to $2.0 million.

  • Capricor Therapeutics' Gains from Investment Securities was N/A to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 437.05% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Gains from Investment Securities of $2.0 million as of FY2024, which was up 437.05% from $367,422 recorded in FY2023.
  • Capricor Therapeutics' 5-year Gains from Investment Securities high stood at $2.0 million for FY2024, and its period low was $51,044 during FY2021.
  • In the last 3 years, Capricor Therapeutics' Gains from Investment Securities had a median value of $867,854 in 2022 and averaged $1.1 million.
  • Per our database at Business Quant, Capricor Therapeutics' Gains from Investment Securities spiked by 1,600.21% in 2022 and then tumbled by 57.66% in 2023.
  • Capricor Therapeutics' Gains from Investment Securities (Yearly) stood at $51,044 in 2021, then spiked by 1,600.21% to $867,854 in 2022, then slumped by 57.66% to $367,422 in 2023, then spiked by 437.05% to $2.0 million in 2024.